Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2026)

TScan Therapeutics has reported Share-based Compensation over the past 6 years, most recently at $2.0 million for Q4 2025.

  • Quarterly Share-based Compensation fell 26.01% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, up 22.59% year-over-year, with the annual reading at $11.7 million for FY2025, 22.59% up from the prior year.
  • Share-based Compensation was $2.0 million for Q4 2025 at TScan Therapeutics, down from $3.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $3.4 million in Q1 2025 and troughed at $344000.0 in Q1 2021.
  • The 5-year median for Share-based Compensation is $1.3 million (2022), against an average of $1.7 million.
  • Year-over-year, Share-based Compensation soared 591.41% in 2021 and then fell 26.01% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $784000.0 in 2021, then surged by 65.43% to $1.3 million in 2022, then rose by 15.65% to $1.5 million in 2023, then soared by 80.93% to $2.7 million in 2024, then fell by 26.01% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Share-based Compensation are $2.0 million (Q4 2025), $3.0 million (Q3 2025), and $3.3 million (Q2 2025).